Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low- and Middle-Income Countries: A Systematic Literature Review

Health Economics (United Kingdom)

Volumn 25, Issue , 2016, Pages 124-139

  Drake, Tom L ^a,b   Devine, Angela ^a,b   Yeung, Shunmay ^c   Day, Nicholas P J ^a,b   White, Lisa J ^a,b   Lubell, Yoel ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MAHIDOL UNIVERSITY   (Thailand)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

dynamic transmission modelling; economic evaluation; infectious disease; low income

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BED NET; CALCULATION; DISEASE CARRIER; DISEASE TRANSMISSION; DYNAMIC TRANSMISSION MODEL; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION PREVENTION; LOWEST INCOME GROUP; MALARIA; MASS SCREENING; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MIDDLE INCOME GROUP; MOSQUITO; NONHUMAN; PRIORITY JOURNAL; SOCIOECONOMICS; SYSTEMATIC REVIEW (TOPIC); COMMUNICABLE DISEASE; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; ECONOMICS; HEALTH ECONOMICS; HEALTH SERVICES RESEARCH; PROCEDURES; TRANSMISSION;

COMMUNICABLE DISEASES; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; ECONOMICS, MEDICAL; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS;

EID: 84956582416     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.3303     Document Type: Article

References (79)

1. Agusto FB, Adekunle AI,. 2014. Optimal control of a two-strain tuberculosis-HIV/AIDS co-infection model. Biosystems 119: 20-44. DOI: 10.1016/j.biosystems.2014.03.006.
2. Alistar S, Grant P, Bendavid E,. 2014a. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Medicine 12: 46.
3. Alistar SS, Owens DK, Brandeau ML,. 2014b. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLoS ONE 9: e86584. DOI: 10.1371/journal.pone.0086584.
4. Babigumira JB, Levin A, Burgess C, Garrison LP, Bauch CT, Braka F, Mbabazi WB, Nabyonga JO, Simons E, Dabbagh A,. 2011. Assessing the cost-effectiveness of measles elimination in uganda: local impact of a global eradication program. Journal of Infectious Diseases 204: S116-S123. DOI: 10.1093/infdis/jir132.
5. Bärnighausen T, Bloom DE, Humair S,. 2012. Economics of antiretroviral treatment vs. circumcision for HIV prevention. Proceedings of the National Academy of Sciences of the United States of America 109: 21271-21276. DOI: 10.1073/pnas.1209017110.
6. Bishai D, Johns B, Nair D, Nabyonga-Orem J, Fiona-Makmot B, Simons E, Dabbagh A,. 2011. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda. Journal of Infectious Diseases 204: S107-S115. DOI: 10.1093/infdis/jir131.
7. Briet OJ, Chitnis N,. 2013. Effects of changing mosquito host searching behaviour on the cost effectiveness of a mass distribution of long-lasting, insecticidal nets: a modelling study. Malaria Journal 12: 215. DOI: 10.1186/1475-2875-12-215.
8. Briët OJ, Penny MA,. 2013. Repeated mass distributions and continuous distribution of long-lasting insecticidal nets: modelling sustainability of health benefits from mosquito nets, depending on case management. Malaria Journal 12: 401. DOI: 10.1186/1475-2875-12-401.
9. Briët OJ, Penny MA, Hardy D, Awolola TS, Bortel WV, Corbel V, Dabiré RK, Etang J, Koudou BG, Tungu PK, Chitnis N,. 2013. Effects of pyrethroid resistance on the cost effectiveness of a mass distribution of long-lasting insecticidal nets: a modelling study. Malaria Journal 12: 77. DOI: 10.1186/1475-2875-12-77.
10. Briggs A, Sculpher M, Claxton K,. 2006. Decision Modelling for Health Economic Evaluation (1st edn). Oxford University Press: UK.
11. Carrasco LR, Lee VJ, Chen MI, Matchar DB, Thompson JP, Cook AR,. 2011. Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective. Journal of the Royal Society Interface 8: 1307-1313. DOI: 10.1098/rsif.2010.0715.
12. Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, Currier J, Wood R, Holmes CB, Pillay S, Conradie F, McIntyre J, Losina E, Walensky RP,. 2011. First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS (London, England) 25: 479-492. DOI: 10.1097/QAD.0b013e3283428cbe.
13. Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB,. 2013. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS (London, England) 27: 447-458. DOI: 10.1097/QAD.0b013e32835ca2dd.
14. Crowell V, Briët O, Hardy D, Chitnis N, Maire N, Pasquale A, Smith T,. 2013. Modelling the cost-effectiveness of mass screening and treatment for reducing Plasmodium falciparum malaria burden. Malaria Journal 12: 4.
15. Dieleman JL, Graves CM, Templin T, Johnson E, Baral R, Leach-Kemon K, Haakenstad AM, Murray CJL,. 2014. Global health development assistance remained steady in 2013 but did not align with recipients' disease burden. Health Affairs (Millwood) 33: 878-886. DOI: 10.1377/hlthaff.2013.1432.
16. Dowdy DW, Houben R, Cohen T, Pai M, Cobelens F, Vassall A, Menzies NA, Gomez GB, Langley I, Squire SB, White R, for the TB MAC meeting participants. 2014. Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling. The International Journal of Tuberculosis and Lung Disease 18: 1012-1018. DOI: 10.5588/ijtld.13.0851.
17. Drake T,. 2014. Priority setting in global health: towards a minimum DALY value. Health Economics 23: 248-252. DOI: 10.1002/hec.2925.
18. Drake TL, Chalabi Z, Coker R,. 2012. Cost-effectiveness analysis of pandemic influenza preparedness: what's missing? Bulletin of the World Health Organization 90: 940-941. DOI: 10.2471/BLT.12.109025.
19. Drummond MF, Sculpher MJ, Torrance GW,. 2005. Methods for the Economic Evaluation of Health Care Programs. Oxford University Press: UK.
20. Durham D, Mbah M, Medlock J, Luz P, Meyers L, Paltiel A, Galvani A,. 2013. Dengue dynamics and vaccine cost-effectiveness in Brazil. Vaccine 31: 3957-3961.
21. Dye C,. 2013. Making wider use of the world's most widely used vaccine: Bacille Calmette-Guérin revaccination reconsidered. Journal of the Royal Society Interface 10: 20130365:. DOI: 10.1098/rsif.2013.0365.
22. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JAC, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily M-C, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DAMC, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB,. 2014. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Global Health 2: e23-e34. DOI: 10.1016/S2214-109X(13)70172-4.
23. Enns EA, Brandeau ML, Igeme TK, Bendavid E,. 2011. Assessing effectiveness and cost-effectiveness of concurrency reduction for HIV prevention. International Journal of STD and AIDS 22: 558-567. DOI: 10.1258/ijsa.2011.010322.
24. Fitzpatrick MC, Hampson K, Cleaveland S, Mzimbiri I, Lankester F, Lembo T, Meyers LA, Paltiel AD, Galvani AP,. 2014. Cost-effectiveness of canine vaccination to prevent human rabies in rural Tanzania. Annals of Internal Medicine 160: 91-100.
25. Freiesleben de Blasio B, Flem E, Latipov R, Kuatbaeva A, Kristiansen IS,. 2014. Dynamic modeling of cost-effectiveness of rotavirus vaccination, Kazakhstan. Emerging Infectious Diseases 20: 29-37. DOI: 10.3201/eid2001.130019.
26. Giglio N, Gentile A, Lees L, Micone P, Armoni J, Reygrobellet C, Crepey P,. 2012. Public health and economic benefits of new pediatric influenza vaccination programs in Argentina. Human Vaccines and Immunotherapeutics 8: 312-322. DOI: 10.4161/hv.18569.
27. Gomez GB, Borquez A, Caceres CF, Segura ER, Grant RM, Garnett GP, Hallett TB,. 2012. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS Medicine 9: e1001323. DOI: 10.1371/journal.pmed.1001323.
28. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C,. 2013. The cost and impact of scaling up pre-exposure prophylaxis for hiv prevention: a systematic review of cost-effectiveness modelling studies. PLoS Medicine 10: e1001401. DOI: 10.1371/journal.pmed.1001401.
29. Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, Sabin ML, Makhlouf-Obermeyer C, De Filippo Mack C, Williams P, Jones L, Smyth C, Kutch KA, Ying-Ru L, Vitoria M, Souteyrand Y, Crowley S, Korenromp EL, Williams BG,. 2012. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS ONE 7: e30216. DOI: 10.1371/journal.pone.0030216.
30. Hontelez JAC, Nagelkerke N, Bärnighausen T, Bakker R, Tanser F, Newell M-L, Lurie MN, Baltussen R, de Vlas SJ,. 2011. The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model. Vaccine 29: 6100-6106. DOI: 10.1016/j.vaccine.2011.06.059.
31. Hontelez JAC, Lurie MN, Barnighausen T, Bakker R, Baltussen R, Tanser F, Hallett TB, Newell M-L, de Vlas SJ,. 2013. Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study. PLoS Medicine 10. DOI: 10.1371/journal.pmed.1001534.
32. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E,. 2013. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Medicine 11: 80. DOI: 10.1186/1741-7015-11-80.
33. Hutton DW, Brandeau ML,. 2013. Too much of a good thing? When to stop catch-up vaccination. Medical Decision Making: An International journal of the Society for Medical Decision Making 33: 920-936. DOI: 10.1177/0272989X13493142.
34. Jit DM, Brisson M,. 2011. Modelling the epidemiology of infectious diseases for decision analysis. PharmacoEconomics 29: 371-386. DOI: 10.2165/11539960-000000000-00000.
35. Kato M, Granich R, Bui DD, Tran HV, Nadol P, Jacka D, Sabin K, Suthar AB, Mesquita F, Lo YR, Williams B,. 2013. The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: towards elimination of HIV transmission. Journal of Acquired Immune Deficiency Syndromes 63: e142-e149. DOI: 10.1097/QAI.0b013e31829b535b.
36. Kawai K, de Araujo GTB, Fonseca M, Pillsbury M, Singhal PK,. 2012. Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model. BMC Infectious Diseases 12: 250. DOI: 10.1186/1471-2334-12-250.
37. Keebler D, Revill P, Braithwaite S, Phillips A, Blaser N, Borquez A, Cambiano V, Ciaranello A, Estill J, Gray R, Hill A, Keiser O, Kessler J, Menzies NA, Nucifora KA, Vizcaya LS, Walker S, Welte A, Easterbrook P, Doherty M, Hirnschall G, Hallett TB,. 2014. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Lancet Global Health 2: e35-e43. DOI: 10.1016/S2214-109X(13)70048-2.
38. Laxminarayan R,. 2004. Act Now or Later? Economics of Malaria Resistance. American Journal of Tropical Medicine and Hygiene 71: 187-195.
39. Laxminarayan R, Over M, Smith DL,. 2006. Will a global subsidy of new antimalarials delay the emergence of resistance and save lives? Health Affairs (Millwood) 25: 325-336. DOI: 10.1377/hlthaff.25.2.325.
40. Levin A, Burgess C, Garrison LP, Bauch C, Babigumira J, Simons E, Dabbagh A,. 2011. Global eradication of measles: an epidemiologic and economic evaluation. Journal of Infectious Diseases 204: S98-S106. DOI: 10.1093/infdis/jir096.
41. Li G, Rabitz H, Yelvington PE, Oluwole OO, Bacon F, Kolb CE, Schoendorf J,. 2010. Global sensitivity analysis for systems with independent and/or correlated inputs. Journal of Physical Chemistry A 114: 6022-6032. DOI: 10.1021/jp9096919.
42. Li J, Gilmour S, Zhang H, Koyanagi A, Shibuya K,. 2012. The epidemiological impact and cost-effectiveness of HIV testing, antiretroviral treatment and harm reduction programs. AIDS (London, England) 26: 2069-2078. DOI: 10.1097/QAD.0b013e3283574e54.
43. Long EF, Stavert RR,. 2013. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis. Journal of General Internal Medicine 28: 1294-1301. DOI: 10.1007/s11606-013-2417-1.
44. Lubell Y,. 2014. Investment in malaria elimination: a leap of faith in need of direction. Lancet Global Health 2: e63-e64. DOI: 10.1016/S2214-109X(14)70005-1.
45. Luz PM, Vanni T, Medlock J, Paltiel AD, Galvani AP,. 2011. Dengue vector control strategies in an urban setting: an economic modelling assessment. Lancet 377: 1673-1680. DOI: 10.1016/S0140-6736(11)60246-8.
46. Maire N, Shillcutt S, Walker D, Tediosi F, Smith T,. 2011. Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research 14: 1028-1038.
47. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S,. 2015. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bulletin of the World Health Organization 93: 118-124. DOI: 10.2471/BLT.14.138206.
48. Mbah M, Kjetland E, Atkins K, Poolman E, Orenstein E, Meyers L, Townsend J, Galvani A,. 2013a. Cost-effectiveness of a community-based intervention for reducing the transmission of Schistosoma haematobium and HIV in Africa. Proceedings of the National Academy of Sciences of the United States of America 110: 7952-7957.
49. Mbah M, Poolman E, Atkins K, Orenstein E, Meyers L, Townsend J, Galvani A,. 2013b. Potential cost-effectiveness of schistosomiasis treatment for reducing HIV transmission in Africa-the case of Zimbabwean women. PLoS Neglected Tropical Diseases 7: e2346.
50. Mbonigaba J,. 2013. Modeling the Cost-effectiveness of HIV/AIDS Interventions in Different Socio-economic Contexts in South Africa, (2007-2020). Mediterranean Journal of Social Sciences 4: 587.
51. Menzies NA, Cohen T, Lin H-H, Murray M, Salomon JA,. 2012. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Medicine 9: e1001347. DOI: 10.1371/journal.pmed.1001347.
52. Nichols BE, Boucher CAB, van Dijk JH, Thuma PE, Nouwen JL, Baltussen R, van de Wijgert J, Sloot PMA, van de Vijver DAMC,. 2013. Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural zambia: a modeling study. PLoS ONE 8: e59549. DOI: 10.1371/journal.pone.0059549.
53. Okell LC, Cairns M, Griffin JT, Ferguson NM, Tarning J, Jagoe G, Hugo P, Baker M, D'Alessandro U, Bousema T, Ubben D, Ghani AC,. 2014. Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. Nature Communications 5: 5606. DOI: 10.1038/ncomms6606.
54. Okosun KO, Makinde OD,. 2012. On a drug-resistant malaria model with susceptible individuals without access to basic amenities. Journal of Biological Physics 38: 507-530. DOI: 10.1007/s10867-012-9269-5.
55. Okosun KO, Ouifki R, Marcus N,. 2011. Optimal control analysis of a malaria disease transmission model that includes treatment and vaccination with waning immunity. Biosystems 106: 136-145. DOI: 10.1016/j.biosystems.2011.07.006.
56. Okosun KO, Rachid O, Marcus N,. 2013. Optimal control strategies and cost-effectiveness analysis of a malaria model. Biosystems 111: 83-101. DOI: 10.1016/j.biosystems.2012.09.008.
57. Palombi L, Bernava GM, Nucita A, Giglio P, Liotta G, Nielsen-Saines K, Orlando S, Mancinelli S, Buonomo E, Scarcella P, Altan AMD, Guidotti G, Ceffa S, Haswell J, Zimba I, Magid NA, Marazzi MC,. 2012. Predicting trends in HIV-1 sexual transmission in sub-Saharan Africa through the Drug Resource Enhancement Against AIDS and Malnutrition model: antiretrovirals for 5 reduction of population infectivity, incidence and prevalence at the district level. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 55: 268-275. DOI: 10.1093/cid/cis380.
58. Pérez Velasco R, Praditsitthikorn N, Wichmann K, Mohara A, Kotirum S, Tantivess S, Vallenas C, Harmanci H, Teerawattananon Y,. 2012. Systematic review of economic evaluations of preparedness strategies and interventions against influenza pandemics. PLoS ONE 7: e30333. DOI: 10.1371/journal.pone.0030333.
59. Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, Brisson M,. 2012. Dynamic transmission modeling a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5. Medical Decision Making 32: 712-721. DOI: 10.1177/0272989X12454578.
60. Pitt C, Goodman C, Hanson K,. 2016. Economic evaluation in global perspective: A bibliometric analysis of the recent literature. Health Economics 25: S1.
61. Prinja S, Bahuguna P, Rudra S, Gupta I, Kaur M, Mehendale SM, Chatterjee S, Panda S, Kumar R,. 2011. Cost effectiveness of targeted HIV prevention interventions for female sex workers in India. Sexually Transmitted Infections 87: 354-361. DOI: 10.1136/sti.2010.047829.
62. Reiner R, Perkins T, Barker C, Niu T, Chaves LF, Ellis A, George D, Menach A, Pulliam J, Bisanzio D, Buckee C, Chiyaka C, Cummings D, Garcia A, Gatton M, Gething P, Hartley D, Johnston G, Klein E, Michael E, Lindsay S, Lloyd A, Pigott D, Reisen W, Ruktanonchai N, Singh B, Tatem A, Kitron U, Hay S, Scott T, Smith D,. 2013. A systematic review of mathematical models of mosquito-borne pathogen transmission: 1970-2010. Journal of the Royal Society Interface 10: 20120921.
63. Revill P, Walker S, Claxton K, Sculpher M,. 2014. Using cost-effectiveness thresholds to determine value for money in low-and middle-income country healthcare systems: are current international norms fit for purpose? Research Paper No. CHE 98, University of York.
64. Ross A, Maire N, Sicuri E, Smith T, Conteh L,. 2011. Determinants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and children. PLoS ONE 6: e18391. DOI: 10.1371/journal.pone.0018391.
65. Sardar T, Mukhopadhyay S, Bhowmick AR, Chattopadhyay J,. 2013. An optimal cost effectiveness study on Zimbabwe cholera seasonal data from 2008-2011. PLoS ONE 8. DOI: 10.1371/journal.pone.0081231.
66. Sartori AM, de Soárez PC, Novaes HM, Amaku M, de Azevedo RS, Moreira RC, Pereira LM, Ximenes RA, Martelli CM,. 2012. Cost-effectiveness analysis of universal childhood hepatitis A vaccination in Brazil: regional analyses according to the endemic context. Vaccine 30: 7489-7497. DOI: 10.1016/j.vaccine.2012.10.056.
67. Scott Braithwaite R, Nucifora KA, Toohey C, Kessler J, Uhler LM, Mentor SM, Keebler D, Hallett T,. 2014. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa? AIDS (London, England) 28 (Suppl 1): S73-S83. DOI: 10.1097/QAD.0000000000000110.
68. Stuckey EM, Stevenson J, Galactionova K, Baidjoe AY, Bousema T, Odongo W, Kariuki S, Drakeley C, Smith TA, Cox J, Chitnis N,. 2014. Modeling the cost effectiveness of malaria control interventions in the highlands of Western Kenya. PLoS ONE 9: e107700. DOI: 10.1371/journal.pone.0107700.
69. Tediosi F, Hutton G, Maire N, Smith T, Ross A, Tanner M,. 2006. Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania. American Journal of Tropical Medicine and Hygiene 75: 131-143.
70. Tediosi F, Maire N, Penny M, Studer A, Smith TA,. 2009. Simulation of the cost-effectiveness of malaria vaccines. Malaria Journal 8: 127. DOI: 10.1186/1475-2875-8-127.
71. Terris-Prestholt F, Foss AM, Cox AP, Heise L, Meyer-Rath G, Delany-Moretlwe S, Mertenskoetter T, Rees H, Vickerman P, Watts CH,. 2014. Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices. BMC Infectious Diseases 14: 14. DOI: 10.1186/1471-2334-14-14.
72. Vanni T, Mendes Luz P, Foss A, Mesa-Frias M, Legood R,. 2012. Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: a dynamic individual-based approach. Vaccine 30: 4866-4871. DOI: 10.1016/j.vaccine.2012.04.087.
73. Verguet S, Stalcup M, Walsh JA,. 2013. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa? Sexually Transmitted Infections 89: 628-634. DOI: 10.1136/sextrans-2012-050891.
74. Von Wyl V, Cambiano V, Jordan MR, Bertagnolio S, Miners A, Pillay D, Lundgren J, Phillips AN,. 2012. Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. PLoS ONE 7:. DOI: 10.1371/journal.pone.0042834.
75. Wagner BG, Blower S,. 2012. Universal access to HIV treatment versus universal "test and treat": transmission, drug resistance & treatment costs. PLoS ONE 7: e41212. DOI: 10.1371/journal.pone.0041212.
76. Walensky RP, Park J-E, Wood R, Freedberg KA, Scott CA, Bekker L-G, Losina E, Mayer KH, Seage GR, Paltiel AD,. 2012. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 54: 1504-1513. DOI: 10.1093/cid/cis225.
77. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, Nakamura YM, Godbole SV, Panchia R, Sanne I, Weinstein MC, Losina E, Mayer KH, Chen YQ, Wang L, McCauley M, Gamble T, Seage GR, Cohen MS, Freedberg KA,. 2013. Cost-Effectiveness of HIV treatment as prevention in serodiscordant couples. New England Journal of Medicine 369: 1715-1725. DOI: 10.1056/NEJMsa1214720.
78. Winetsky DE, Negoescu DM, DeMarchis EH, Almukhamedova O, Dooronbekova A, Pulatov D, Vezhnina N, Owens DK, Goldhaber-Fiebert JD,. 2012. Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and Eastern Europe: a cost-effectiveness analysis. PLoS Medicine 9: e1001348. DOI: 10.1371/journal.pmed.1001348.
79. World Bank. Country Classifications. (Available at: http://data.worldbank.org/news/new-country-classifications accessed 1.26.15).